LambdaVision is a biotechnology company focused on developing a protein-based artificial retina to restore vision for patients with retinal degenerative diseases. They are pioneering the use of microgravity on the International Space Station (ISS) to improve the manufacturing process of these retinas. LambdaVision partners with organizations like NASA and Space Tango to conduct research and development in low Earth orbit, aiming for commercial-scale production of artificial retinas. Their work involves space-based manufacturing, microgravity research, and biomedical applications.
All verified mentions of this organization in source documents.
LambdaVision’s next ISS investigation will focus on increasing production volume and optimizing the manufacturing process.
LambdaVision has reserved capacity on Starlab to continue in-orbit manufacturing after the International Space Station is retired.
LambdaVision is developing an automated production system to manufacture a protein-based artificial retina at commercial scale.
LambdaVision has pre-booked commercial space in low-Earth orbit through partnerships with Starlab Space LLC, a joint venture led by Voyager Technologies.
LambdaVision recently closed a $7 million seed funding round co-led by Seven Seven Six and Aurelia Foundry Fund with additional support from Seraphim Space, providing runway into 2027.
LambdaVision leverages microgravity to improve its layer-by-layer production process for an artificial retina composed of alternating layers of the protein bacteriorhodopsin and a polymer supported by a synthetic fiber membrane.
LambdaVision has reserved payload slots and commercial space on Starlab’s next-generation commercial space station.
LambdaVision plans to scale manufacturing of its protein-based artificial retina in space to benefit people with retinal degenerative diseases on Earth.
To date, LambdaVision has secured $22.0 million in funding.
Reduced gravity in low-Earth orbit improves homogeneity, stability, and performance of thin films such as LambdaVision’s protein-based artificial retina.
Nicole Wagner, Ph.D., is CEO of LambdaVision.
LambdaVision’s layer-by-layer protein manufacturing platform has potential applications for highly uniform, stable protein films in biosensors, optical systems, tissue engineering, and drug delivery.
LambdaVision’s space-based manufacturing plans are intended to prepare the company for the scheduled 2030 retirement of the International Space Station.
LambdaVision has launched nine missions to the International Space Station.
LambdaVision has flown nine missions to the International Space Station.
Manufacturing in microgravity allows LambdaVision to build a higher-performance membrane with increased stability compared to manufacturing on Earth.
LambdaVision manufactures artificial retinas in low Earth orbit.
LambdaVision developed and refined its process of manufacturing artificial retinas on the ISS.
LambdaVision pre-booked manufacturing time and space onboard Starlab Space’s yet-to-be-launched commercial space station.
LambdaVision’s partnership with Starlab will allow the company to continue leveraging low Earth orbit to advance its protein-based artificial retina toward commercialization and to lay groundwork for other potential commercial efforts in LEO.